Cargando…

Low dose of lenalidmide and PI3K/mTOR inhibitor trigger synergistic cytoxicity in activated B cell-like subtype of diffuse large B cell lymphoma

BACKGROUND: Activated B cell-like subtype of diffuse large B cell lymphoma (ABC-DLBCL) presents aggressive clinical courses and poor prognosis. Targeting key pathways may raise the possibility of improving clinical outcomes. METHODS: The synergetic effects were assessed by CCK-8 assay and measured b...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jin, Zhen, Qing, Kai, Ouyang, Yuan, Liu, Zhao, Wang, Wenfang, Li, Xiaoyang, Xu, Zizhen, Li, Junmin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4806505/ https://www.ncbi.nlm.nih.gov/pubmed/27009084 http://dx.doi.org/10.1186/s13046-016-0327-x

Ejemplares similares

Synergistic effect of oridonin and a PI3K/mTOR inhibitor on the non-germinal center B cell-like subtype of diffuse large B cell lymphoma
por: Qing, Kai, et al.
Publicado: (2016)

The preservative polyquaternium-1 increases cytoxicity and NF-kappaB linked inflammation in human corneal epithelial cells
por: Paimela, Tuomas, et al.
Publicado: (2012)

Synergistic targeting of the PI3K/mTOR and MAPK/ERK pathways in Merkel cell carcinoma
por: Temblador, Arturo, et al.
Publicado: (2022)

Pyrimidines-Based Heterocyclic Compounds: Synthesis, Cytoxicity Evaluation and Molecular Docking
por: El-Atawy, Mohamed A., et al.
Publicado: (2022)

Cytoxicity and Apoptotic Mechanism of Ruthenium(II) Amino Acid Complexes in Sarcoma-180 Tumor Cells
por: Lima, Aliny Pereira, et al.
Publicado: (2014)

The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition
por: Haagensen, E J, et al.
Publicado: (2012)

Akt and mTOR in B Cell Activation and Differentiation
por: Limon, Jose J., et al.
Publicado: (2012)

Feedforward and feedback connections and their relation to the cytox modules of V2 in Cebus monkeys
por: Nascimento-Silva, Sheila, et al.
Publicado: (2014)

Vertical inhibition of the PI3K/Akt/mTOR pathway is synergistic in breast cancer
por: Woo, S-U, et al.
Publicado: (2017)

mTOR-Dependent and Independent Survival Signaling by PI3K in B Lymphocytes
por: Kaileh, Mary, et al.
Publicado: (2016)

The Role of mTOR Inhibitors for the Treatment of B-Cell Lymphomas
por: Argyriou, Pinelopi, et al.
Publicado: (2012)

All PI3Kinase signaling is not mTOR: dissecting mTOR-dependent and independent signaling pathways in T cells
por: Gamper, Christopher J., et al.
Publicado: (2012)

Cucurbitacin B and SCH772984 exhibit synergistic anti-pancreatic cancer activities by suppressing EGFR, PI3K/Akt/mTOR, STAT3 and ERK signaling
por: Zhou, Jingkai, et al.
Publicado: (2017)

Targeting the PI3K/AKT/mTOR/NFκB Axis in Ovarian Cancer
por: Ghoneum, Alia, et al.
Publicado: (2020)

Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells
por: Grabinski, Nicole, et al.
Publicado: (2012)

Synergistic Effects of Combination Therapy with AKT and mTOR Inhibitors on Bladder Cancer Cells
por: Kim, Hyera, et al.
Publicado: (2020)

Synergistic Anti-Tumor Effect of mTOR Inhibitors with Irinotecan on Colon Cancer Cells
por: Reita, Damien, et al.
Publicado: (2019)

The PI3K/Akt/mTOR pathway is involved in CVB3-induced autophagy of HeLa cells
por: Chang, Huan, et al.
Publicado: (2017)

Knockdown of Rap1b Enhances Apoptosis and Autophagy in Gastric Cancer Cells via the PI3K/Akt/mTOR Pathway
por: Li, Yazhou, et al.
Publicado: (2016)

Gefitinib induces lung cancer cell autophagy and apoptosis via blockade of the PI3K/AKT/mTOR pathway
por: ZHAO, ZHONG-QUAN, et al.
Publicado: (2016)

Synergistic anticancer effects of everolimus (RAD001) and Rhein on gastric cancer cells via phosphoinositide-3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) pathway
por: Gao, Feng, et al.
Publicado: (2022)

Synergistic inhibition of colon cancer cell growth with nanoemulsion-loaded paclitaxel and PI3K/mTOR dual inhibitor BEZ235 through apoptosis
por: Zou, Hong, et al.
Publicado: (2016)

Evaluation of In Vitro Cytoxicity and Genotoxicity of Size-Fractionated Air Particles Sampled during Road Tunnel Construction
por: Dominici, Luca, et al.
Publicado: (2013)

mTOR activity in AIDS-related diffuse large B-cell lymphoma
por: Browne, Sara H., et al.
Publicado: (2017)

The Role of mTOR in B Cell Lymphoid Malignancies: Biologic and Therapeutic Aspects
por: Karatrasoglou, Eleni A., et al.
Publicado: (2023)

Combined HASPIN and mTOR inhibition is synergistic against KRAS-driven carcinomas
por: Xu, Chenyue, et al.
Publicado: (2022)

Cyclopamine and Rapamycin Synergistically Inhibit mTOR Signalling in Mouse Hepatocytes, Revealing an Interaction of Hedgehog and mTor Signalling in the Liver
por: Spormann, Luise, et al.
Publicado: (2020)

Low-frequency ultrasound enhances chemotherapy sensitivity and induces autophagy in PTX-resistant PC-3 cells via the endoplasmic reticulum stress-mediated PI3K/Akt/mTOR signaling pathway
por: Wu, Yuqi, et al.
Publicado: (2018)

SH2B1 promotes NSCLC cell proliferation through PI3K/Akt/mTOR signaling cascade
por: Wang, Shaoqiang, et al.
Publicado: (2018)

miR-196b regulates gastric cancer cell proliferation and invasion via PI3K/AKT/mTOR signaling pathway
por: LI, NA, et al.
Publicado: (2016)

Synergistic effects of inhibiting the MNK-eIF4E and PI3K/AKT/ mTOR pathways on cell migration in MDA-MB-231 cells
por: Lineham, Ella, et al.
Publicado: (2018)

Hepatitis B virus X protein induces expression of alpha-fetoprotein and activates PI3K/mTOR signaling pathway in liver cells
por: Zhu, Mingyue, et al.
Publicado: (2015)

MYO18B promotes hepatocellular carcinoma progression by activating PI3K/AKT/mTOR signaling pathway
por: Zhang, Zhenyu, et al.
Publicado: (2018)

Synergistic efficacy of inhibiting MYCN and mTOR signaling against neuroblastoma
por: Kling, Matthew J., et al.
Publicado: (2021)

Multipoint targeting of the PI3K/mTOR pathway in mesothelioma
por: Zhou, S, et al.
Publicado: (2014)

NVP-BEZ235, a dual PI3K/mTOR inhibitor synergistically potentiates the antitumor effects of cisplatin in bladder cancer cells
por: MOON, DU G., et al.
Publicado: (2014)

Combined PI3Kα-mTOR Targeting of Glioma Stem Cells
por: Eckerdt, Frank D., et al.
Publicado: (2020)

Curcumin and Plumbagin Synergistically Target the PI3K/Akt/mTOR Pathway: A Prospective Role in Cancer Treatment
por: Ahmad, Iftikhar, et al.
Publicado: (2023)

Walking the tightrope: UCH-L1 as an mTOR inhibitor and B-cell oncogene
por: Bedekovics, Tibor, et al.
Publicado: (2019)

PI3K/AKT/mTOR Pathway in Angiogenesis
por: Karar, Jayashree, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_v3fd2plpo0nl2d3iqsdgcbfe8o